Loading
The GCIG criteria define when a fall in the CA-125 blood test counts as a response, and when a rise counts as progression, for ovarian cancer.
The Gynecological Cancer Intergroup had agreed criteria for defining progression-free survival after first-line treatment and response in recurrent disease using CA-125. Rustin and colleagues (International Journal of Gynecological Cancer 2011) wrote detailed definitions that incorporate RECIST 1.1, for use in trial protocols; by then the progression criteria had been validated for recurrent disease. They were developed in patients on chemotherapy and had not been validated with targeted drugs.
Shares CA-125, Ovarian cancer.
Shares CA-125, Ovarian cancer.
Shares CA-125, Ovarian cancer.
Shares CA-125, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/